The incremental clinical advantage from CAPTAIN (penile length preservation, plus prior erectile/continence results) supports broader TULSA adoption and may drive procedure volume growth. The stock could trade up near-term as analysts update models. Key catalyst to watch: 1-year primary safety endpoint and 3-year primary efficacy endpoint of CAPTAIN.
Price Chart
Executive Summary
Profound Medical announced new CAPTAIN trial data showing statistically significant superior penile length preservation with the TULSA Procedure vs robotic radical prostatectomy (no median change vs 0.65 cm reduction at 1 month, p<0.001). This adds to previously reported safety endpoint advantages in erectile function and urinary continence, strengthening the clinical value proposition for TULSA.
Key Facts
- CAPTAIN trial: no median change in penile length at 1 month after whole-gland TULSA vs 0.65 cm median reduction after robotic RP
- Between-arm difference statistically significant (0.42 cm, p<0.001)
- Data presented at Society of Robotic Surgery Annual Meeting, July 24, 2026
- Previously announced CAPTAIN primary safety endpoint showed TULSA superiority in preserving erectile function and urinary continence at 6 months
Financial Impact
Positive clinical data strengthens TULSA's competitive position vs robotic prostatectomy but no financial figures disclosed in this filing
Risk Factors
- CAPTAIN primary efficacy endpoint (3-year treatment-free survival) remains unread
- Market adoption and reimbursement decisions may lag clinical data
- Competitive response from robotic surgery platforms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (PROF) — Batch item 1 | 0001171843-26-004863 |
| Exhibit: exh_991.htm | 0001171843-26-004863 |
| Document: 0001171843-26-004863-index-headers.html | 0001171843-26-004863 |
| Document: 0001171843-26-004863-index.html | 0001171843-26-004863 |
| Document: 0001171843-26-004863.txt | 0001171843-26-004863 |
| 8-K Filing (PROF) — Batch item 6 | 0001171843-26-004863 |
| Exhibit: exh_991.htm | 0001171843-26-004863 |
| Document: 0001171843-26-004863-index-headers.html | 0001171843-26-004863 |
| Document: 0001171843-26-004863-index.html | 0001171843-26-004863 |
| Document: 0001171843-26-004863.txt | 0001171843-26-004863 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 8-K | $6.89 $5.81 | ▼ −15.67% | ▼ −14.47% | $5.85 (−15.09%) |
Sep 3, 2026 29d ago | 8-K | $6.80 $5.97 | ▼ −12.21% | ▼ −11.06% | $5.85 (−13.97%) |
Aug 17, 2026 6w ago | 8-K | $6.55 $6.80 | ▲ +3.82% | ▲ +5.01% | $5.85 (−10.69%) |
Aug 17, 2026 6w ago | 8-K | $6.55 $6.80 | ▲ +3.82% | ▲ +5.01% | $5.85 (−10.69%) |
Jul 24, 2026 10w ago | 8-K | $7.26 $7.25 | ▼ −0.14% | ▼ −0.51% | $5.85 (−19.42%) |
Jul 15, 2026 11w ago | 8-K | $6.96 $6.99 | ▲ +0.43% | ▲ +1.41% | $5.85 (−15.95%) |
May 14, 2026 20w ago | 8-K | $6.97 $6.83 | ▼ −2.01% | ▼ −2.97% | $5.85 (−16.07%) |
May 12, 2026 20w ago | S-3 | $7.10 $6.73 | ▼ −5.21% | ▼ −4.05% | $5.85 (−17.61%) |
Apr 16, 2026 24w ago | 8-K | $6.62 $6.75 | ▲ +1.96% | ▲ +0.98% | $5.85 (−11.63%) |
Apr 14, 2026 24w ago | 8-K | $6.26 $6.84 | ▲ +9.27% | ▲ +7.87% | $5.85 (−6.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access